Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, appears to act by binding to and activating the GHRH receptor on somatotrophs in the pituitary gland
This additional receptor activation allows researchers to investigate whether triple-pathway modulation produces different metabolic outcomes compared to dual-agonist compounds
There is no long-term, randomized, outcome-based human trial demonstrating that GHRP-2 slows aging or produces durable benefit in healthy people
Angiogenesis and Vascular Formation Research has examined these peptides' effects on new blood vessel formation in various tissue models
Citations Citations to this article as recorded by Beyond Cyclic Nucleotides: Emerging Roles of Phosphodiesterases in Metabolic Disorders Nicole Bertani, Maria Rita Assenza, Francesca Sciarra, Giorgia DAddato, Francesca Gioia Klinger, Mary Anna Venneri, Andrea M
DAMPs also impact Kupffer cells, activating the nucleotide-binding oligomerization domain-like receptor (NLR) Family, Pyrin Domain-Containing 3 protein (NLRP3), a type of inflammasome leading to IL-1 secretion and inflammation, and pyroptosis, releasing more DAMPs and perpetuating a destructive cycle (Hammerich and Tacke, 2023)